Interpretation of results of clinical trials in coronary thrombolysis

Fibrinolysis and Proteolysis

Volumn 11, Issue SUPPL. 2, 1997, Pages 17-21

  Sobel, B E ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT PROTEIN; ANTITHROMBIN; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN; RECOMBINANT STAPHYLOKINASE; RETEPLASE; STAPHYLOKINASE; STREPTOKINASE; TICK ANTICOAGULANT PEPTIDE; TISSUE PLASMINOGEN ACTIVATOR DERIVATIVE; UNCLASSIFIED DRUG; UROKINASE;

ANGIOCARDIOGRAPHY; BLEEDING; BLOOD CLOT LYSIS; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; DRUG MECHANISM; HEART INFARCTION; HUMAN; INTRACORONARY INFUSION; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0030718563     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80065-3     Document Type: Conference Paper

References (41)

1. Sobel B E. Infarct size, prognosis, and causal contiguity. Circulation 1976; 53(Suppl. I): I-146-148.
2. Sobel B E, Furberg C D. Surrogates, semantics and sensible public policy. Special Commentary. Circulation 1997; 95: 1661-1663
3. Messerli F H. Whatever happened to the calcium antagonist controversy? J Am Coll Cardiol 1996; 28: 12-13.
4. Sherry S. The fibrinolytic system and its pharmacologic activation for thrombolysis. In: Sobel B E, ed. Cardiology Clinics: Thrombolysis and the Heart. Philadelphia: W. B. Saunders, 1987: 1-11.
5. European Cooperative Study Group for Streptokinase Treatment in Acute Myocardial Infarction: Streptokinase in acute myocardial infarction. N Engl J Med 1979; 301: 797-802.
6. DeWood M A, Spores J, Notske R N, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902.
7. Sobel B E. The impact of time to treatment on the efficacy of coronary thrombolysis. In: Sobel B E, Collen D, eds. Coronary Thrombolysis in Perspective. Principles Underlying Conjunctive and Adjunctive Therapy. New York: Marcel Dekker, 1993: 65-76.
8. Torr S R, Nachowiak D A, Fujii S, Sobel B E. 'Plasminogen steal' and clot lysis. J Am Coll Cardiol 1992; 19: 1085-1090.
9. Eisenberg P R, Sobel B E, Jaffe A S. Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1992; 19: 1065-1069.
10. Sobel B E, Hirsh J. Editorial: Principles and practice of coronary thrombolysis and conjunctive treatment. Am J Cardiol 1991; 68: 382-388.
11. Bleich S D, Nichols T C, Schumacher R R, Cooke D H, Tate D A, Teichman S L. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990; 66: 1412-1417.
12. Chazov E L, Matteeva L S, Mazaev A V, et al. Intracoronary administration of fibrinolysis in acute myocardial infarction. Ter Arkh 1976; 48: 8-19.
13. Rentrop P, Blanka H, Karsch K R, et al. Acute myocardial infarction: intracoronary application of nitroglycerin and Streptokinase in combination with transluminal recanalization. Clin Cardiol 1979; 2: 354-363.
14. Fletcher A P, Sherry S, Alkjaersig N, Smyrniotis F E, Fick S. The maintenance of a sustained thrombolytic state in man. II. Clinical observations on patients with myocardial infarction and other thromboembolic disorders. J Clin Invest 1959; 38: 1111-1119.
15. Anderson J L, Rothbard R L, Hackworthy R A, et al. Multicenter reperfusion trial of intravenous anisoylated plasminogen Streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase. J Am Coll Cardiol 1988; 11: 1153-1163.
16. Bates E R, Califf R M, Stack R S, et al. Thrombolysis and angioplasty in myocardial infarction (TAMI-1) trial: influence of infarct location on arterial patency, left ventricular function and mortality. J Am Coll Cardiol 1989; 13: 12-18.
17. Chesebro J H, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trrial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76: 142-154.
18. Sobel B E. Thrombolysis in the treatment of acute myocardial infarction. In: Fuster V, Verstraete M, eds. Thrombosis in Cardiovascular Disorders. Philadelphia: W. B. Saunders, 1992: 289-326.
19. Collen D. Trials comparing the available thrombolytic agents. Coron Artery Dis 1992; 3: 117-122.
20. The ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1998; ii: 349-360.
21. ISIS-3 Collaborative Group. ISIS-3: a randomized comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-770.
22. GISSI-2 and International Study Group. Six-month survival in 20891 patients with acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Eur Heart J 1992; 13: 1692-1697.
23. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682.
24. Rogers W J, Tiefenbrunn A J, French W J, et al. National Registry of Myocardial Infarction-Phase 1: 354 435 patients depicting evolving practice patterns in the United States. Eur Heart J 1996; 17: 25 (abstract).
25. Lenderink T, Simoons M L, Van Es G-A, Van de Werf F, Verstraete M, Arnold A E R, European Cooperative Study Group. Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. Circulation 1995; 92: 1110-1116.
26. Ito H, Okamura A, Iwakura K, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996; 93: 1993-1999.
27. Sobel B E. Conundrums in coronary thrombolysis: The TIMI-II/TIMI-III flow dichotomy and the denominator problem. Coron Artery Dis 1996; 7: 81-82.
28. Smalling R W, Bode C, Kalbfleisch J, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of retaplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995; 91: 2725-2732.
29. Ewald G A, Eisenberg P R. Plasmin-mediated activation of contact system in response to pharmacological thrombolysis. Circulation 1995; 91: 28-36.
30. Abendschein D R, Meng Y Y, Torr-Brown S, Sobel B E. Maintenance of coronary patency after fibrinolysis with tissue factors pathway inhibitor. Circulation 1995; 92: 944-949.
31. Rodriguez R, Collen D, Lijnen H R. Binding of streptokinase and staphylokinase to plasminogen. Fibrinolysis 1995; 9: 298-303.
32. Vanderschueren S, Barrios L, Kerdsinchai P, et al. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995; 92: 2044-2049.
33. Keyt B A, Paoni N F, Bennett W F. Site-directed mutagenesis of tissue-type plasminogen activator. In: Cleland J L, Craik C S, eds. Protein Engineering: Principles and Practice. New York: Wiley-Liss, 1996; 435-466.
34. Cannon C P, McCabe C H, Henry T D, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial. J Am Coll Cardiol 1994; 23: 993-1003.
35. Antman E M, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 1994; 90: 1624-1630.
36. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Ha Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631-1637.
37. Neuhaus K-L, v Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) Study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK). Circulation 1994; 90: 1638-1642.
38. Sobel B E. Intracranial bleeding, fibrinolysis, and anticoagulation: causal connections and clinical implications. Circulation 1994; 90: 2147-2152.
39. Laroche Y, DeMeutter J, Messens J, Lauwereys M. High-level secretion and very efficient isotopic labeling of tick anticoagulant peptide (TAP) expressed in the methylotrophic yeast, Pichia pastoris. Biotechnology 1994; 12: 1119-1124.
40. Coller B S, Anderson K, Weisman H F. New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb Haemost 1995; 74: 302-308.
41. Kasolka-Magdeleine N, Durrieu-Jais C, Coste P, Besse P. Low molecular weight heparin versus regular heparin after myocardial infarction treated by intravenous thrombolysis. Eur Heart J 1996; 17: 121 (abstract).